Goodbye needles, hello nanopatch

Based in Brisbane this medical device company for vaccine delivery is using a game-changing micro-needle technology (NanopatchTM) developed at the University of Queensland.

Prof. Mark Kendall who heads the research team developing the Nanopatch received the Translational Research Excellence Commercialisation Award for the Nanopatch and Vaxxas was a finalist in
the Enterprize Business Plan competition in 2010.

Vaxxas has attracted $15 million of investment to continue development of the Nanopatch and take it to clinical trials. Investors, led by OneVentures, include Brandon Capital, the Medical Research
Commercialisation Fund (MRCF) and US-based HealthCare Ventures.

Related Stories
Microscopy for Medtech

MTPConnect helping us help medtech – Press Release

AMMRF Technical Voucher Fund receives funding from MTPConnect’s Project Fund Program Recognised as a big, bold idea to improve the productivity, competitiveness and innovative capacity of Australia’s medtech, biotech and pharmaceutical ...


Hazer Group live on ASX

Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and high-grade synthetic graphite from natural gas and iron ore. Its development depended on AMMRF microscopy @ UWA. They have announced the successful ...


Fast-tracking elastin to market

Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been awarded a $1million Translation Award from the Wellcome Trust to fast track their elastin-based synthetic skin to clinical trials. They will refine and ...